To compare the diagnostic performance and image quality of a deep-learning-assisted ultra-fast biparametric MRI (bpMRI) with the conventional multiparametric MRI (mpMRI) for the diagnosis of clinically significant prostate cancer (csPCa).
This prospective single-center study enrolled 123 biopsy-naïve patients undergoing conventional mpMRI and additionally ultra-fast bpMRI at 3 T between 06/2023-02/2024. Two radiologists (R1: 4 years and R2: 3 years of experience) independently assigned PI-RADS scores (PI-RADS v2.1) and assessed image quality (mPI-QUAL score) in two blinded study readouts. Weighted Cohen's Kappa (κ) was calculated to evaluate inter-reader agreement. Diagnostic performance was analyzed using clinical data and histopathological results from clinically indicated biopsies.
Inter-reader agreement was good for both mpMRI (κ = 0.83) and ultra-fast bpMRI (κ = 0.87). Both readers demonstrated high sensitivity (≥94 %/≥91 %, R1/R2) and NPV (≥96 %/≥95 %) for csPCa detection using both protocols. The more experienced reader mostly showed notably higher specificity (≥77 %/≥53 %), PPV (≥62 %/≥45 %), and diagnostic accuracy (≥82 %/≥65 %) compared to the less experienced reader. There was no significant difference in the diagnostic performance of correctly identifying csPCa between both protocols (p > 0.05). The ultra-fast bpMRI protocol had significantly better image quality ratings (p < 0.001) and achieved a reduction in scan time of 80 % compared to conventional mpMRI.
Deep-learning-assisted ultra-fast bpMRI protocols offer a promising alternative to conventional mpMRI for diagnosing csPCa in biopsy-naïve patients with comparable inter-reader agreement and diagnostic performance at superior image quality. However, reader experience remains essential for diagnostic performance.
European journal of radiology open. 2025 Jan 21*** epublish ***
Antonia M Pausch, Vivien Filleböck, Clara Elsner, Niels J Rupp, Daniel Eberli, Andreas M Hötker
Diagnostic and Interventional Radiology, University Hospital Zurich, Switzerland., Department of Pathology and Molecular Pathology, University Hospital Zurich, Switzerland., Department of Urology, University Hospital Zurich, Switzerland.